Can Platelet-Rich Plasma Enhance Anterior Cruciate Ligament and Meniscal Repair?

Ian D. Hutchinson, MD1 Scott A. Rodeo, MD2 Gabriel S. Perrone, MS3 Martha M. Murray, MD3

1 Department of Orthopaedic Surgery, Wake Forest Baptist Health, Winston Salem, North Carolina
2 Sports Medicine and Shoulder Service, Hospital for Special Surgery, New York, New York
3 Department of Orthopaedic Surgery, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts

Address for correspondence Scott A. Rodeo, MD, Sports Medicine and Shoulder Service, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021 (e-mail: rodeos@hss.edu).

Abstract

The use of platelet-rich plasma (PRP) to improve clinical outcome following a soft tissue injury, regeneration, and repair has been the subject of intense investigation and discussion. This article endeavors to relate clinical and basic science strategies focused on biological augmentation of the healing response in anterior cruciate ligament (ACL) and meniscus repair and replacement using PRP. Therein, a translational feedback loop is created in the literature and targeted towards the entire multidisciplinary team. Ultimately, it is hoped that the theoretical benefits of PRP on soft-tissue interfacial healing will emerge clinically following a careful, focused characterization at the benchtop, and prospective randomized controlled clinical study.

Keywords

- ACL
- meniscus
- PRP
- biologics
- meniscal repair
- ACL reconstruction

Intra-articular tissues such as the anterior cruciate ligament (ACL) and meniscus have an intrinsically poor healing capacity. This has led to an intense interest in discovering methods to augment the biological responsiveness of cells in these tissues. Platelet-rich plasma (PRP) contains various growth factors, including transforming growth factor-β1 (TGF-β1), fibroblast growth factor-2 (FGF-2), insulin-like growth factor (IGF-1), epidermal growth factor, platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF) that have demonstrated positive effects on cell proliferation, cell migration, angiogenesis, and extracellular matrix production in numerous cell types both in vivo and in vitro models.1-5 The primary cell in the ACL is the fibroblast. The fibroblast has receptors for many of the growth factors released by platelets, including PDGF, TGF-β, and FGF. PDGF (Table 1) stimulates fibroblast growth, migration, and biosynthetic activity.6 Similar effects are seen with TGF-β and FGF. In vitro, ACL cell migration has been stimulated by TGF-β1, while PDGF and FGF stimulate cell proliferation in a three-dimensional (3D) collagen scaffold.7 In this review, we will explore the current data relating to the use of PRP and related materials in the augmentation of ACL and meniscus healing.

The current surgical treatment for ACL injuries is ACL reconstruction where the torn ACL is replaced with a graft of the tendon. However, the recent research has focused on the use of platelets and PRP to heal the injured ligament, rather than replace it. These studies have not yet progressed to a clinical trial, and in this section we will review the basic science behind the preclinical development of this new technique.

Previous studies have demonstrated that ligaments which exist outside of joints (extra-articular) heal with an orderly progression of events. The first basic process is bleeding and then formation of a fibrin–platelet clot within the wound site, which fills in the gap between the torn ends of the tissue and forms a provisional scaffold for the surrounding cells to move into and remodel into a functional scar. However, in the intra-articular environment, after an injury, there is an upregulated production of urokinase plasminogen activator by synoviocytes (Fig. 1), which converts the inactive plasminogen molecule present in synovial fluid into its active form, plasmin.8 Plasmin quickly degrades fibrin. Therefore, if a tissue is

received March 25, 2014
accepted after revision June 25, 2014
published online August 7, 2014

ISSN 1538-8506.
exposed to synovial fluid after injury, the ends may bleed, but the fibrin is unable to form a stable clot as it is degraded too quickly.\textsuperscript{9–11} The early loss of this provisional scaffold has been thought to be a major reason why tissues within joints, such as the ACL or meniscus, fail to heal after the injury.\textsuperscript{9,10}

PRP has been evaluated in animal models to stimulate healing of the ACL with suture repair; unfortunately, it has been found to be ineffective.\textsuperscript{12} In a larger animal study using 4-month-old Yorkshire pigs, the addition of a \textsuperscript{3/4}PRP to the suture repairs did not improve knee laxity or the maximum tensile load of the suture repairs after 14 weeks in vivo. The strength of all repairs at 14 weeks was less than 11\% of the intact ligaments, suggesting minimal healing with all repairs.\textsuperscript{12} The use of PRP therefore, may have failed because the main structural protein within PRP is also fibrin. Therefore, the fibrin in the PRP is degraded by the active plasmin within the joint and the PRP is unable to stay in the ACL wound site. Interestingly, when collagen is combined with fibrin, a copolymer is formed which is resistant to degradation by plasmin.\textsuperscript{13} Further studies using a collagen-based scaffold material to deliver the PRP have had greater success in stimulating ACL healing in animal models as the carrier stabilizes and protects the fibrin and platelets in the ACL wound site.\textsuperscript{14–16}

\textbf{Collagen—Platelet Composites in Anterior Cruciate Ligament Repair}

While the use of PRP alone was ineffective at stimulating ACL healing and repair, the use of PRP in combination with an

### Table 1 Growth factors associated with PRP

<table>
<thead>
<tr>
<th>Name</th>
<th>Effect</th>
<th>Source\textsuperscript{b}</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platelet-derived growth factor</td>
<td>Proliferation, migration, angiogenesis, and collagen production</td>
<td>Platelets</td>
</tr>
<tr>
<td>Platelet-derived angiogenesis factor</td>
<td>Stimulation of proliferation of endothelial cells and angiogenesis</td>
<td>Platelets</td>
</tr>
<tr>
<td>Platelet-derived endothelial growth factor</td>
<td>Stimulate wound healing via proliferation of fibroblasts and keratinocytes</td>
<td>Platelets</td>
</tr>
<tr>
<td>Platelet factor 4</td>
<td>Stimulates migration of neutrophils, acts as chemoattractant for fibroblasts, heparin antagonist</td>
<td>Platelets</td>
</tr>
<tr>
<td>Vascular endothelial growth factor</td>
<td>Angiogenesis and unclear effect on fibroblasts</td>
<td>Platelets</td>
</tr>
<tr>
<td>Transforming growth factor-(\beta)1</td>
<td>Proliferation, differentiation, collagen production, and fibronectin production</td>
<td>Platelets</td>
</tr>
<tr>
<td>Transforming growth factor-(\beta)2</td>
<td>Embryonic development and wound healing</td>
<td>Platelets</td>
</tr>
<tr>
<td>Fibroblast growth factor</td>
<td>Fibroblast and myoblast stimulation</td>
<td>Platelets</td>
</tr>
<tr>
<td>Epidermal growth factor</td>
<td>Cell proliferation (mesenchymal and epithelial). Complex interaction with other growth factors</td>
<td>Platelets</td>
</tr>
<tr>
<td>Hepatocyte growth factor</td>
<td>Migration, angiogenesis, and antifibrotic effect</td>
<td>Plasma\textsuperscript{c}</td>
</tr>
<tr>
<td>Insulin-like growth factor-1</td>
<td>Fibroblast and myoblast stimulation, muscle growth and regeneration</td>
<td>Plasma\textsuperscript{c}</td>
</tr>
</tbody>
</table>

Abbreviation: PRP, platelet-rich plasma.

Source: Reprinted with permission from Murray et al.\textsuperscript{94}

\textsuperscript{a}As known.

\textsuperscript{b}Some growth factors are released from the cells other than platelets.

\textsuperscript{c}All growth factors are not released by the platelets.
extracellular matrix protein scaffold containing collagen has resulted in a new technique for ACL treatment. This treatment of "bio-enhanced ACL repair" has been evaluated in two recent large animal studies in the porcine model, both of which reported no significant difference in mechanical properties when the bio-enhanced ACL repair and ACL reconstruction using an allograft tendon were compared at 3 months and 1 year after the surgery. The mean values for yield load and linear stiffness were higher in the bio-enhanced repair group at 3 months; however, these differences were not statistically significant, possibly due in part to the variability seen in both the groups. In addition, at 3 months, the mean values for the anteroposterior laxity of the knee were lower in the bio-enhanced ACL repair group than in the ACL reconstructed group, although again, these differences were not statistically significant, which may also be due in part to the variability in both the groups. For the porcine knees studied at 1 year after ACL repair (Fig. 1) using bioenhancement with an extracellular matrix scaffold loaded with whole blood resulted in repairs with the same maximum load, stiffness, and knee laxity as animals treated with a bone-patellar tendon-bone allograft, but the animals treated with bio-enhanced repair had no more cartilage damage at 1 year than the contralateral knee, while the animals treated with ACL reconstruction had large lesions noted, particularly on the medial femoral condyle, which is the same anatomic location seen in human patients at 10 to 15 years after ACL reconstruction.

The 1-year study in the porcine model referred to above used whole blood as the biological adjuvant. It is possible that the results would be even better if a higher concentration of platelets were used in the form of PRP placed within a carrier to allow it to persist for a long enough period in the wound site. It has previously been reported that biological relationships are not always linear, but are often confined to a small window of effectiveness (i.e., the dose–response curve is not linear). In addition, as PRP is a stimulator of other cells, a higher concentration may or may not be helpful because its effects are dependent on the presence of responsive cells. If only a limited number of cells capable of responding are available, then the highest concentration of PRP may not be able to produce a result better than a lower concentration. Finally, while there is evidence for many positive effects of PRP on wound healing, there is also an evidence for some negative effects. It is not known how higher concentrations of platelets affect the balance between positive and negative effects of PRP.

Experimental data examining the effect of various concentrations of platelets in PRP on ACL cells in vitro and in vivo have been performed. The use of higher concentrations of platelets (3× or 5×) in vitro were not as effective as 1× platelet preparations at simulating types I and III collagen gene expression and cell metabolism and preventing apoptosis. Increasing the platelet concentration in vivo from 3× to 5× did not result in any improvement in the structural properties of the healing ACL, although the group treated with 5× PRP did have a higher cell number seen in the healing tissue. While not statistically significant, the means of the mechanical properties of the group treated with the 3× platelet concentration were better than the 5× group. Thus, in vitro and in vivo data currently suggests that the use of concentrations of platelets greater than 1× within extracellular matrix scaffolds may not be as effective at stimulating ACL healing as physiologic concentrations.

Another study in pigs evaluated the performance of a 5× platelet composite to enhance ACL graft healing. These data provide encouragement regarding the efficacy of the platelet-enhanced ACL reconstruction approach in immature animals. Significant improvements in the graft tensile properties were found with the use of the 5× PRP–collageen composite with a 60% increase in failure load of the graft and decreased laxity of the PRP knees at 3 months after surgery. These data provide encouragement regarding the efficacy of the platelet-enhanced ACL reconstruction approach in immature animals.

However, when a similar study was performed in adolescent animals, the results were not as promising. The use of a 1× PL–collagen composite resulted in improved stiffness of the graft, but higher concentrations (3× and 5×) did not. The use of the collagen–platelet composite did, however, result in less cartilage damage to the knees when evaluated.
at 3 months after surgery than the knees treated with graft reconstruction alone.31

While no clinical trials for the use of collagen–platelet composites have been conducted till date, several clinical studies evaluating the effect of the addition of exogenous platelets on graft healing have been performed. A recent systematic review identified eight studies, seven of which focused on graft maturation and five on bone–tendon healing in the tunnel.32 Four of the seven studies reported significantly better maturation “outcomes” in the grafts treated with concentrated platelets compared with those that were not.33–36 In one study, evaluation of the grafts with magnetic resonance imaging (MRI) revealed that the signal intensity of a graft treated with 9× platelet solution at the time of surgery matched that of the intact ACL in 100% of the patients as compared with only 78% of those treated with a graft alone at 6 months after surgery.33 However, no differences in clinical outcomes between the treated and untreated groups were reported.33 A second study using MRI also found that the use of a 9× platelet concentrate reduced the average time to achieve a normal MRI signal intensity value from 369 to 177 days.35 Qualitatively, it has been observed that grafts treated with concentrated platelets (3 ×) showed higher arthroscopic ratings for synovial coverage, graft width, and graft tension in the platelet-treated group when compared with the controls.34 Histology revealed that the ligament maturity index36 was significantly greater in the platelet-treated grafts.34 Other studies have found no differences between the grafts treated with platelets versus untreated grafts in any outcome measures.37–39

The majority of studies evaluating graft–bone healing have found no improvements in healing at the graft–bone junction.33,36,38,40 In summary, the review of the literature suggests that the use of platelet concentrates may improve the rate at which grafts achieve low-signal intensity on MRI or an improved ligament maturity index on histology33–35, however, none of them showed an improvement of clinical or patient oriented outcome even at 2 years,32,33,36,39 or significantly improved bone–tendon healing.33,36,38,40

The results of the preliminary studies provide credence to the concept of bio-enhancing healing of an ACL graft with the application of platelets at the time of surgery. However, only two of the eight clinical studies that have been published meet the standards of level 1 evidence and none of them report long-term outcomes (> 2 years). Thus, the effects of these concentrated platelet preparations on cartilage health and overall knee joint function after ACL injury and reconstruction remain unknown. In addition, the PRP and platelet concentrate formulations used in the various studies differed not only in platelet concentration, but also in the concentration of white blood cells and PRP activation technique. It is extremely likely that the other blood constituents in some of the preparations of PRP (i.e., leukocytes, erythrocytes) may be important in ACL graft healing.41 As noted earlier, for ACL repair, the delivery of the platelet preparation may also prove to be important for graft healing as well. Future studies will be required to find the best way to deliver a platelet preparation, as well as how to optimize the biologic adjunct to maximally stimulate the healing response of the graft, and to improve the long-term outcomes after ACL reconstruction, particularly in terms of preventing the development of posttraumatic osteoarthritis.

**Biological Enhancement of Meniscal Restoration**

The meniscus functions in the knee joint by distributing load, improving congruency, enhancing stability, and provides joint lubrication contributing to the reproducible articulation between the femur and the tibia.2,5 When the integrity of the meniscus is disrupted, contact stresses are increased, leading to a well-established association with osteoarthritis.42–45 Thus, current treatment paradigms advocate for meniscal restoration where possible and biological strategies have focused on expanding operative intervention to allow repair and healing of tears with unfavorable healing characteristics.5 The use of exogenous fibrin clot is representative of earlier augmentation techniques in meniscal repair and has demonstrated some success in animal and clinical studies despite the technical difficulties of keeping the clot in situ at the repair site.46–49

Vascularization of the meniscus is inextricably linked to the success of meniscal repair and delineates zonal variations in cellular and biochemical composition of the meniscal tissue.2 During prenatal development the meniscus is a fully vascularized and relatively homogenous tissue; during childhood, there is a regression of the peripheral vascularization. By the age of 10 years, the peripheral (10–30%) meniscus is vascularized and this changes minimally to 10 to 25% by skeletal maturity.50 For the purpose of preclinical study and clinical correlation, the meniscus has been divided into three zones: the red–red zone (vascularized), red–white zone (partial vascularization), and white–white zone (avascular). Biological augmentation techniques have been focused on improving clinical outcome for tears that extend into the avascular zone.51

When specific tear or patient characteristics are unfavorable for primary repair, partial or total meniscectomy is often undertaken to relieve patient symptoms.52 In orthopedic centers currently outside the United States, biodegradable meniscal scaffolds (Collagen meniscus implant, Ivy Sports Medicine, Montvale, NJ; Actifit, Orteq Limited, London, United Kingdom) are implanted immediately following partial meniscectomy in knees that demonstrate minimal degenerative cartilage changes; ligamentous repair, cartilage restoration, and realignment procedures may be performed concomitantly.5 The goal of implanting a meniscal scaffold is to promote meniscal tissue regeneration on a 3D matrix in the defect space. Scaffolds are fixed to adjacent meniscal tissue from the peripheral rim through the body of the meniscus using sutures; the meniscal–scaffold interface often extends from the red–red vascularized zone to the inner white–white avascular zone. Cellular infiltration and matrix deposition across the meniscus–scaffold interface (constituting biological integration) are critical for the success of meniscal scaffolds that have been associated with promising
Platelet-Rich Plasma: Potential Benefits in Biologically Unfavorable Meniscal Tears

The various cytokines in PRP are known to positively affect fibrochondrocyte migration and extracellular matrix production in vitro. Accordingly, Ishida et al reported a preclinical study of the effects of PRP on meniscal tissue regeneration using a gelatin hydrogel. In their study, PRP was prepared using a double spin technique. The in vitro section of the study investigated the effects of PRP on rabbit fibrochondrocytes harvested from the inner two-thirds of the meniscus; specifically, PRP was compared with platelet poor plasma (PPP) and in the control group the media was supplemented with 1% fetal bovine serum (FBS). Platelet counts were recorded and growth factor compositional analysis revealed significantly more PDGF-BB, TGF-β1, and VEGF in the PRP compared with the PPP. In vitro results demonstrated the significant positive effects of PRP on cell viability/proliferation and matrix production (sulfated GAG). Gene expression analysis revealed no difference in type I collagen expression, significant upregulation of biglycan and decorin, and significant downregulation of aggrecan expression in the PRP-treated cells. During the in vivo study arm, 30 µL of PRP was incorporated in cross-linked, lyophilized gelatin hydrogels in a dropwise fashion, and the hydrogel was incubated for 1 hour to facilitate PRP incorporation. Hydrogel groups (PRP, PPP, and control—phosphate buffered saline) were implanted in a 1.5 mm defect in the anterior inner two-thirds of the meniscus in skeletal mature rabbits. A semiquantitative repair scoring system was used based on histological analysis (hematoxylin-eosin and safranin-O). The findings demonstrated increased tissue bonding, fibrochondrocyte number, and GAG matrix in the PRP group as compared with the PPP and the control at 4, 8, and 12 weeks. The hydrogel persisted to the 4 week time point and the increased tissue regeneration trends in the PRP group were significant at 12 weeks. Of note, the PPP and control groups were seen to have a more fibrous repair with relatively decreased GAG staining. The whole joint assessment revealed slight synovial hypertrophy in some animals (groups not specified) and no clear degeneration of the articular cartilage was found in any group.

Meniscal Tears: Treating the Whole Joint

It is important to remember that the treatment of meniscal deficiency should always be undertaken within the context of treating the whole knee joint. Ultimately, mitigating the effects of temporal or absolute meniscal deficiency on premature knee joint degeneration represents the extended goal of meniscal surgery; patients with untreated meniscal tears have an odds risk of 5.7 of developing osteoarthritis and successful meniscal repair has demonstrated improved long-term outcome. Incorporating the use of PRP in the surgical treatment of biologically unfavorable meniscal tears must account for the knee functioning as an organ with significant interplay of the soft tissues. In this regard, consideration of the delivery and exposure of bioactive growth factors from biologics including PRP is critically important. Intra-articular administration of PRP has been undertaken in patients with acute chondral lesions and symptomatic early joint degeneration. The potential benefits of intra-articular administration of PRP in the setting of meniscal deficiency and repair relates to: (1) anti-inflammatory/anti-catabolic effects within the whole joint impacting the meniscal tissue healing response and the integrity of the unaffected meniscal and articular cartilage tissue and (2) direct stimulation of synoviocytes that have been implicated in contributing to meniscal repair and maintaining the whole joint health. Following acute meniscal (and ACL) injury, proteoglycan fragments in the synovial fluid are seen to peak acutely and persist to at least 4 years. Characterization of the posttraumatic knee joint synovial fluid has documented elevated levels of IL-1β, IL-6, IL-8, IL-10, and tumor necrosis factor (TNF)-α and may account for the release (and increased turnover) of cartilage matrix constituents following injury. Exposure of meniscal tissue to IL-1 and TNF-α has been shown to result in decreased matrix production and GAG composition, particularly in the setting of altered loading; this is likely the consequence of activation of catabolic pathways involving nitric oxide, matrix metalloproteinases, and prostaglandin E2. It follows that using an established in vitro model of meniscal repair, McNulty and colleagues demonstrated the detrimental effects of IL-1 and TNF-α on simulated meniscal tear healing in vitro; enhanced integrative repair of the porcine meniscal tissue was subsequently achieved following inhibition of IL-1 and TNF-α. PRP has been demonstrated to have anti-inflammatory properties through its effects on the canonical nuclear factor κB signaling pathway in multiple cell types, including synoviocytes and chondrocytes. Sundman et al demonstrated this effect of
PRP on knee joint tissues using cocultured chondrocytes and synoviocytes harvested from osteoarthritic patients. In their study, treatment of the osteoarthritic cocultures with PRP decreased concentrations of TNF-α released into the media (IL-β1 levels were undetectable overall).16 Degenerative meniscal tears in arthritic joints are generally considered unsuitable for repair and are often resected in symptomatic patients who fail conservative measures. However, emerging evidence from Stone et al, suggests that the arthritic meniscus may play an active biological role in knee joint degeneration and patients with degenerative tears may also benefit from an anti-inflammatory effect of PRP.17

Intra-articular administration of PRP in the presence of an acute meniscal tear in an otherwise healthy knee may also be of benefit by directly stimulating synoviocytes in the knee joint. Synovial fibroblasts (type B synoviocytes) have previously been implicated to contribute to meniscal repair and tissue regeneration using meniscal scaffolds.46,78,79 In addition, synoviocytes (types A and B) have been recruited in surgical strategies to improve outcome following meniscal repair including synovial advancement flap, synovial–meniscal rasping, and conduits from abaxial synovial perimeniscal capillary plexus to the repair site.80 In the equine model, coculture of synoviocytes and chondrocytes from the site of an acute cartilage injury demonstrated a protective effect of healthy synoviocyte coculture in preventing the damaged chondrocytes from developing an osteoarthritis phenotype in vitro, suggesting that they may have a role in maintaining knee joint health following acute soft tissue injury.81 However, it has recently been suggested by Braun et al that PRP composition may be particularly important when targeting synoviocytes during intra-articular administration; in their study leukocyte-rich PRP and red blood cells (RBCs) resulted in synoviocyte cell death and proinflammatory mediator production.82 Based on these findings, the authors recommend leukocyte poor, RBC-free PRP formulations for intra-articular administration.

**Meniscal Tears: Targeting the Tear Interface**

Treatment strategies using PRP may also be customized to target the tear interface directly. Some PRP preparations have adhesive properties, although these are likely to be short lived in the acutely injured joint secondary to the increased plasmin, as previously discussed. Therefore, not unlike the use of blood clot, a significant limitation of in situ PRP administration to the tear interface is delivery—maintaining position and directing bioactive growth factors to the surrounding tissue.46,47 Delivering PRP using a scaffold or hydrogel matrix represents a potential solution to this problem, as demonstrated in vivo.60,83 Of particular interest are collagen-based scaffolds and hydrogels given that; (1) the collagen–fibrin copolymer is resistant to degradation by plasmin; (2) collagen scaffolds are already used in the treatment of meniscal defects, and (3) collagen matrices have been used to deliver biologics to meniscal tears.13,84,85

Platelet-rich fibrin (PRF) represents an exciting alternative to PRP in targeting interfascial biological augmentation of meniscal repair. In addition to having increased ease of surgical handling, PRF provides a growth factor-laden 3D matrix environment, facilitating cellular population across the tear interface.86,87 PRF has demonstrated increased and prolonged release of TGF-β1, a growth factor shown to improve meniscal healing, as compared with blood clots, in vitro.3,86 Zumstein et al characterized growth factor release from leukocyte and platelet rich fibrin (L-PRF) and whole blood and demonstrated increased and prolonged release of growth factors, including TGF-β1, IGF-1, PDGF-AB, and VEGF. In a subsequent prospective controlled pilot study, the same group demonstrated increased early vascularization (6 weeks) of rotator cuff repair in tears treated with PRF; it is postulated that increased vascularization may ultimately increase early cellular responses during healing.88 Preliminary data from ongoing in vitro work in the senior author’s laboratory (S. A. R.) suggests that PRF may increase fibrochondrocyte migration to a simulated meniscal tear interface. Using a novel, one-dimensional meniscal explant growth factor diffusion model (Fig. 2), directional cell migration was stimulated through explant tissue by PRF and was compared with blood clotting and control (empty) study groups. Briefly, the red–white zone mature bovine explants were cultured in full media (10% FBS) and cellular migration was determined by parameterizing the cellular distribution in

**Fig. 2**  (A) PRF matrices were prepared using peripheral venous blood that was centrifuged at 400g for 12 minutes using a table-top centrifuge specifically designed for this application. The PRF was then allowed to congeal on a custom draining system after which, the PRF was cored using a 6-mm biopsy punch and sandwiched between the two meniscal cores. (B) A schematic representation of the simulated meniscal interface in vitro. Within the 6-mm cloning tube, a one-dimensional growth factor diffusion gradient is created (yellow arrows). PRF, platelet-rich fibrin. (Image courtesy of Marco Demange, MD and Michael Schär, Hospital for Special Surgery, New York, NY.)
the explant relative to the simulated interface; cells were counted using a manual subtraction technique of CD-45 (general hematopoietic cell marker—excluding platelets and erythrocytes) and 4',6-diamidino-2-phenylindole-stained cells in the explants (Fig. 3). Cell migration to the simulated interface was significantly increased in the PRF group at 28 days (p < 0.05 for N = 6).

**Future Meniscal Repair Augmentation: Cells, Scaffolds, and Biologics**

Regardless of the method of administration or physical form of the biologic, quantitative biological characterization of the repair process is significant to ensure impactful clinical translation. It is clear that PRP may vary significantly depending on processing. Recently, Howard et al. suggested that differential PRP preparation techniques may result in different amounts of constituent growth factors from the same donor samples. In their study, the simple centrifuge protocol technique resulted in the highest IGF-1 release and the SmartPrep technique (Harvest Technologies Corp., Plymouth, MA) resulted in the highest levels of TGF-β1 and PDGF-AB. This may hold potential to target differential growth factor delivery (migratory, anabolic, and proliferative) using differential PRP preparation techniques applied to the healing meniscal interface.

As a final point of discussion, the combination of cells, biologic augmentation strategies, and scaffolds holds promise. However, introducing such complexity to meniscal repair preclinical studies at this point may confound interpretation given that respective contributions of PRP, cell types, and specific scaffolds types of meniscal healing remain poorly understood. In an attempt to relate the respective contributions of mesenchymal stem cells (MSCs), bone marrow aspirate, and leukocyte-rich PRP. Zellner et al used a hyaluronan–collagen matrix in the rabbit model in vitro and an in vivo 2-mm punch defect in the avascular zone with outcome measures out to 12 weeks. Their study compared the aforementioned groups head-to-head without combination groups. In the PRP group they failed to find any significant advantage to adding leukocyte-rich PRP to the matrix. Interestingly, undifferentiated MSCs resulted in the best meniscal healing and this was superior to MSCs precultured in chondrogenic medium for 2 weeks. The emerging use of bone marrow aspirate in combination with a collagen matrix using an arthroscopic wrapping technique also holds promise to biologically augment meniscal repair.

**Conclusion**

Overall, the use of biologics in ACL and meniscal surgery has demonstrated some clinical benefit and remains promising, but the existing data should be considered preliminary due to a lack of definitive evidence. At present, objective interpretation of existing clinical and preclinical evidence regarding the use of PRP in ACL and meniscal surgery fails to demonstrate a clear benefit. Perhaps the discrepancy between theoretical benefit and existing evidence may be accounted for by the fact that PRP, and related products, are not currently formulated to meet the specific requirements of a given tissue or biologic environment, although this trend is changing. For example, it seems extremely unlikely that the same preparation techniques (and composition) will be best suited to intra-articular administration to the acutely injured joint, bone tunnel osteointegration in ACL surgery, and meniscal healing at a tear interface. To move forward in this area, tailoring preparation techniques to targeted tissue effects within the joint in
ACL and meniscal surgery represents an optimized platform for further investigation. Whole joint assessment of intra-articular biological strategies will also be essential.

References

The Journal of Knee Surgery Vol. 28 No. 1/2015


Lee CM, Kisiday JD, McIlwraith CW, Grodzinsky AJ, Frisbie DD. Synoviocytes protect cartilage from the effects of injury in vitro. BMC Musculoskeletal Disorders 2013;14:54


Monllau JC, Gelber PE, Abat F, et al. Outcome after partial medial meniscus substitution with the collagen meniscal implant at a minimum of 10 years’ follow-up. Arthroscopy 2011;27(7):933–943

Visser LC, Arnoczky SP, Caballero O, Egerbacher M. Platelet-rich fibrin constructs elute higher concentrations of transforming growth factor-β1 and increase tendon cell proliferation over time when compared to blood clots: a comparative in vitro analysis. Vet Surg 2010;39(7):811–817


